The neutrophil-lymphocyte ratio: considerations for clinical application

Affiliations

¹ Department of Medicine, Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine and Cardiovascular Diseases, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02215, USA.

Comment

Nicholas H Adamstein et al. Eur Heart J. 2021.

. 2021 Jun 7;42(22):2216-2217.

doi: 10.1093/eurheartj/ehab166.

¹ Department of Medicine, Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine and Cardiovascular Diseases, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02215, USA.

No abstract available

Comment on

The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials.
Adamstein NH, MacFadyen JG, Rose LM, Glynn RJ, Dey AK, Libby P, Tabas IA, Mehta NN, Ridker PM. Adamstein NH, et al. Eur Heart J. 2021 Mar 1;42(9):896-903. doi: 10.1093/eurheartj/ehaa1034. Eur Heart J. 2021. PMID: 33417682 Free PMC article.
Neutrophil-lymphocyte ratio in the immune checkpoint inhibitors-related atherosclerosis.
Zhang N, Tse G, Liu T. Zhang N, et al. Eur Heart J. 2021 Jun 7;42(22):2215. doi: 10.1093/eurheartj/ehab158. Eur Heart J. 2021. PMID: 33748846 No abstract available.